FDA granted RMAT designation to Rocket's therapy, and Kinnari Patel was identified as President and Head of R&D.
2 reports, 1 independent
Updated Jul 17
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted RMAT designation to Rocket's therapy, and Kinnari Patel was identified as President and Head of R&D.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Rocket
Nothing else this week.
-
Kinnari Patel
researcher
Nothing else this week.
Coverage
Newest first; wire copies grouped- Business WireRocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy CRANBURY, N.J., July 17, 2025--(BUSINESS
- Unknown outlet